6-(aminomethyl)-2,2-dimethyl-4H-1,3-benzodioxin-4-one | 842137-48-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 6-(aminomethyl)-2,2-dimethyl-4H-1,3-benzodioxin-4-one
• 英文别名: 6-(Aminomethyl)-2,2-dimethyl-1,3-benzodioxin-4-one
• CAS: 842137-48-8
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: IFVJZKKWAYQDLT-UHFFFAOYSA-N

物化性质

• 沸点：
  398.5±42.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,2-dimethyl-4-oxo-4H-1,3-benzodioxine-6-carbonitrile 在 palladium on activated charcoal 氢气 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 22.5h， 以38%的产率得到6-(aminomethyl)-2,2-dimethyl-4H-1,3-benzodioxin-4-one
  参考文献：
  名称：

  [EN] ALKYNYL ARYL CARBOXAMIDES
  [FR] ALKYNYLARYL-CARBOXAMIDES

  摘要：

  本发明涉及式(I')的炔基芳基羧酰胺及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的炎症疾病、肥胖和/或代谢紊乱的使用，包括I型和/或II型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高脂血症、高甘油三酯血症-高胆固醇血症、多囊卵巢综合征(PCOS)。特别是，本发明涉及使用式(I')的炔基芳基羧酰胺来调节，尤其是抑制PTPs的活性。(I') A是C2-C15炔基，C2-C6-炔基芳基，C2-C6-炔基杂芳基。Cy是芳基、杂芳基、环烷基或杂环族；n是0或1。Cy'是一个芳基，它可以选择性地通过一个3-8成员的环烷基融合。R1和R2独立地互选自由氢或(C1-C6)烷基组成的组。R4和R5各自独立地互选自H、羟基。C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基或R4和R5可以形成一个不饱和或饱和的杂环，其中至少R4或R5不是氢或C1-C6烷基。

  公开号：

  WO2005012280A1

文献信息

• Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
  申请人：Naccari Giancarlo

  公开号：US20090118357A1

  公开（公告）日：2009-05-07

  Therefore the present invention relates specifically to the compounds of general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising H, —C n H 2n-1 , a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R 3 is selected from —CO—CH 3 , —NHOH, —OH, —OR 6 in which R 6 is a linear or branched alkyl group having from 1 to 6 carbon atoms; R 4 is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl or allyl; R 5 , R 7 , R 8 are hydrogen atoms; or R 3 and R 4 , R 4 and R 5 , or R 7 and R 8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.

  因此，本发明特别涉及具有通用公式（I）的化合物，其中R1和R2，可以相同或不同，选自包括H，—CnH2n-1，具有1到6个碳原子的直链或支链烷基，或者共同形成一个含有5或6个原子的芳香族或脂肪族环；R3选自—CO—CH3，—NHOH，—OH，—OR6，其中R6是一个具有1到6个碳原子的直链或支链烷基；R4选自H，具有1到6个碳原子的直链或支链烷基，苯基，苄基，—CF3或—CF2CF3，乙烯基或烯丙基；R5，R7，R8是氢原子；或者R3和R4，R4和R5，或R7和R8共同形成一个环，与苯环，芳香族或脂肪族环融合，含有5或6个原子，并包括1到2个独立选自N，O的杂原子，及其在医疗领域的应用。
• Aryl dicarboxamides
  申请人：Thomas J. Russel

  公开号：US20060189583A1

  公开（公告）日：2006-08-24

  The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an aminocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen or C 1 -C 6 -alkyl; R 4 and R 5 are each independently from each other selected from the group consisting of H, hydroxy, C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, C 2 -C 3 alkynyl carboxy, amino or R 4 and R 5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R 4 or R 5 is not a hydrogen or C 1 -C 6 alkyl.

  本发明涉及式（I）的芳基二羧酰胺及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的肥胖症和/或代谢紊乱，包括1型和/或2型糖尿病、不良葡萄糖耐受、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、多囊卵巢综合症（PCOS）。特别地，本发明涉及使用式（I）的芳基二羧酰胺来调节，特别是抑制PTP的活性。其中，A是氨基甲酰基；Cy是芳基、杂环芳基、芳基-杂环芳基、杂环芳基-芳基、芳基-芳基、环烷基或杂环基团；n为0或1；R1和R2各自独立地选择自氢或C1-C6烷基的群；R4和R5各自独立地选择自H、羟基、C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基或R4和R5可以形成不饱和或饱和的杂环环，其中R4或R5中至少有一个不是氢或C1-C6烷基。
• Alkynyl aryl carboxamides
  申请人：Swinnen Dominique

  公开号：US20070105913A1

  公开（公告）日：2007-05-10

  The present invention is related to alkynyl aryl carboxamides of Formula (I′) and use thereof for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia-hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of alkynyl aryl carboxamides of Formula (I′) to modulate, notably to inhibit the activity of PTPs. (I′) A is a C 2 -C 15 alkynyl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl. Cy is an aryl, heteroaryl, cycloalkyl or heterocycle group; n is either 0 or 1. Cy′ is an aryl., which may optionally be fused by a 3-8 membered cycloalkyl. R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen or (C 1 -C 6 )alkyl. R 4 and R 5 are each independently from each other selected from the group consisting of H, hydroxy. C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, C 2 -C 3 alkynyl carboxy, amino or R 4 and R 5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R 4 or R 5 is not a hydrogen or C 1 -C 6 alkyl.

  本发明涉及公式（I'）的炔基芳基羧酰胺及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的炎症性疾病、肥胖和/或代谢紊乱，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酸甘油酯血症-高胆固醇血症、多囊卵巢综合征（PCOS）。特别地，本发明涉及使用公式（I'）的炔基芳基羧酰胺来调节，特别是抑制PTP的活性。 （I'）中，A是C2-C15炔基、C2-C6炔基芳基、C2-C6炔基杂芳基。Cy是芳基、杂芳基、环烷基或杂环基；n为0或1。Cy'是芳基，可以选择与3-8个成员的环烷基融合。R1和R2分别独立地选自羟基或（C1-C6）烷基的群。R4和R5各自独立地选自H、羟基、C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基或R4和R5可以形成不饱和或饱和的杂环，其中R4或R5中至少有一个不是氢或C1-C6烷基。
• ALKYNYL ARYL CARBOXAMIDES
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1654247A1

  公开（公告）日：2006-05-10
• ARYL DICARBOXAMIDES
  申请人：Merck Serono SA

  公开号：EP1656139B1

  公开（公告）日：2011-10-05